1. The Synthetic Surfactant CHF5633 Restores Lung Function and Lung Architecture in Severe Acute Respiratory Distress Syndrome in Adult Rabbits
   Pavol Mikolka et al, 2024, Lung CrossRef
2. Fundamentals of aerosol therapy in critical care
   Jayesh Dhanani et al, 2016, Critical Care CrossRef
3. Pharmacological agents for adults with acute respiratory distress syndrome
   Sharon R Lewis et al, 2019, Cochrane Database of Systematic Reviews CrossRef
4. Microbiome in Acute Respiratory Distress Syndrome (ARDS)
   Gayathri Gopal et al, 2022, Microbiome in Inflammatory Lung Diseases CrossRef
5. Efficacy of Surfactant Therapy of ARDS Induced by Hydrochloric Acid Aspiration Followed by Ventilator-Induced Lung Injury – an Animal Study
   P MIKOLKA et al, 2022, Physiological Research CrossRef
6. Why does COVID-19 disproportionately affect older people?
   Amber L. Mueller et al, 2020, Aging CrossRef
7. Inhalable Vaccines: Can They Help Control Pandemics?
   Vivek Chavda et al, 2022, Vaccines CrossRef
8. Surfactant impairs coagulation in-vitro: A risk factor for pulmonary hemorrhage?
   Tzipora Strauss et al, 2013, Thrombosis Research CrossRef
9. Contemporary procedure for respiratory support in acute respiratory distress syndrome of various genesis (lecture)
   A. V. Vlasenko et al, 2020, Messenger of ANESTHESIOLOGY AND RESUSCITATION CrossRef
10. Emerging drugs for acute lung injury
    Daniela Impellizzeri et al, 2015, Expert Opinion on Emerging Drugs CrossRef
11. Efficacy of Surfactant Therapy of ARDS Induced by Hydrochloric Acid Aspiration Followed by Ventilator-Induced Lung Injury – an Animal Study
    P MIKOLKA et al, 2022, Physiological Research CrossRef
12. Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19
    Christina B. Klouda et al, 2020, Antioxidants CrossRef
13. The Role of Pulmonary Surfactants in the Treatment of Acute Respiratory Distress Syndrome in COVID-19
    Shengguang Wang et al, 2021, Frontiers in Pharmacology CrossRef
14. Effects of interventions on survival in acute respiratory distress syndrome: an umbrella review of 159 published randomized trials and 29 meta-analyses
    Adriano R. Tonelli et al, 2014, Intensive Care Medicine CrossRef
15. Developing an exogenous pulmonary surfactant-glucocorticoids association: Effect of corticoid concentration on the biophysical properties of the surfactant
    Alejandra Cimato et al, 2018, Respiratory Physiology & Neurobiology CrossRef
16. The exogenous surfactant pre-treatment attenuates ventilator-induced lung injury in adult rats
    Rafael Neto Chirico et al, 2022, Respiratory Physiology & Neurobiology CrossRef
17. Pharmacological therapies for acute respiratory distress syndrome
    Peter Markus Spieth et al, 2014, Current Opinion in Critical Care CrossRef
18. Evaluación de la seguridad del uso poscomercial del surfactante cubano, SURFACEN^®, en el tratamiento del síndrome de dificultad respiratoria aguda del adulto
    Yinet Barrese Pérez et al, 2019, NCT Neumología y Cirugía de Tórax CrossRef
19. Phosphatidylglycerol and surfactant: A potential treatment for COVID-19?
    Wendy B. Bollag et al, 2020, Medical Hypotheses CrossRef
20. Severe COVID-19 ARDS Treated by Bronchoalveolar Lavage with Diluted Exogenous Pulmonary Surfactant as Salvage Therapy: In Pursuit of the Holy Grail?
    Barbara Ruaro et al, 2022, Journal of Clinical Medicine CrossRef
21. Co-aerosolized Pulmonary Surfactant and Ambroxol for COVID-19 ARDS Intervention: What Are We Waiting for?
    Pradeep Kumar, 2020, Frontiers in Bioengineering and Biotechnology CrossRef
22. Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury
    Francesco Cattel et al, 2021, Respiratory Physiology & Neurobiology CrossRef
23. Synthetic lung surfactants containing SP-B and SP-C peptides plus novel phospholipase-resistant lipids or glycerophospholipids
    Robert H. Notter et al, 2016, PeerJ CrossRef
24. Sinapultide-Loaded Microbubbles Combined with Ultrasound to Attenuate Lipopolysaccharide-Induced Acute Lung Injury in Mice
    Dong Liu et al, 2020, Drug Design, Development and Therapy CrossRef
25. Surfactant therapies to treat pulmonary disorders in young infants
    P. Biban et al, 2013, Early Human Development CrossRef
26. Adjunctive treatments in pediatric acute respiratory distress syndrome
    Yee Hui Mok et al, 2014, Expert Review of Respiratory Medicine CrossRef
27. The use of surfactant preparations in the absence of primary deficiency: publications, legal and regulatory framework
    S. V. Yargin, 2021, Glavvrač (Chief Medical Officer) CrossRef